Industry
Biotechnology
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 06, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 1:03 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:08 am
Portfolio Pulse from Avi Kapoor
April 24, 2024 | 12:09 pm
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 1:24 pm
Portfolio Pulse from Benzinga Insights
April 23, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
April 23, 2024 | 11:41 am
Portfolio Pulse from Benzinga Insights
April 19, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 19, 2024 | 11:03 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.